Apimeds Pharmaceuticals US, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing Apitox, an intradermally administered bee venom-based toxin. It is focused on developing Apitox as a potential osteoarthritis (OA) treatment for patients with knee pain who failed to respond adequately to conservative non- pharmacologic therapy and simple analgesics.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļAPUS
āļāļ·āđāļāļāļĢāļīāļĐāļąāļApimeds Pharmaceuticals US Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļMay 09, 2025
āļāļĩāļāļĩāđāļMenon (Vin)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ2
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļMay 09
āļāļĩāđāļāļĒāļđāđ100 Matawan Road
āđāļĄāļ·āļāļMATAWAN
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX â NASDAQ Basic Amex
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ07747
āđāļāļĢāļĻāļąāļāļāđ18482015010
āđāļ§āđāļāđāļāļāđhttps://www.apimedsus.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļAPUS
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļMay 09, 2025
āļāļĩāļāļĩāđāļMenon (Vin)
Mr. Erik C. Emerson
President
Mr. Erik C. Emerson
President
Dr. Bennett Weintraub, Ph.D.
Dr. Bennett Weintraub, Ph.D.
Independent Director
Ms. Carol A. O'Donnell
Independent Director
Ms. Elona Kogan, Esq.
Independent Director
Dr. Vin Menon
Chief Executive Officer
Mr. Sungjoon Chae
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
Dr. Bennett Weintraub, Ph.D.
Dr. Bennett Weintraub, Ph.D.
Independent Director
Ms. Carol A. O'Donnell
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Erik C. Emerson
President
Mr. Erik C. Emerson
President
Dr. Bennett Weintraub, Ph.D.
Dr. Bennett Weintraub, Ph.D.
Independent Director
Ms. Carol A. O'Donnell
Independent Director
Ms. Elona Kogan, Esq.
Independent Director